Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.98 USD
Change Today -0.08 / -0.57%
Volume 226.6K
NEOT On Other Exchanges
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

neothetics inc (NEOT) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/20/14 - $14.10
52 Week Low
05/19/15 - $5.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOTHETICS INC (NEOT)

Related News

No related news articles were found.

neothetics inc (NEOT) Related Businessweek News

No Related Businessweek News Found

neothetics inc (NEOT) Details

Neothetics, Inc., a clinical-stage specialty pharmaceutical company, engages in developing therapeutics for the aesthetic market. Its lead product candidate includes LIPO-202, an injectable formulation of salmeterol xinafoate that has completed Phase II development for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The company is also developing LIPO-102, which is an injectable form of salmeterol xinafoate and fluticasone propionate for the treatment of the orphan indication of symptomatic exophthalmos or protrusion of the eye from the orbit associated with thyroid-related eye diseases. The company was formerly known as Lipothera, Inc. and changed its name to Neothetics, Inc. in August 2014. Neothetics, Inc. was founded in 2007 and is headquartered in San Diego, California.

10 Employees
Last Reported Date: 03/26/15
Founded in 2007

neothetics inc (NEOT) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $498.6K
Chief Financial Officer
Total Annual Compensation: $293.6K
Chief Medical Officer
Total Annual Compensation: $368.6K
Chief Scientific Officer
Total Annual Compensation: $413.0K
Compensation as of Fiscal Year 2014.

neothetics inc (NEOT) Key Developments

Neothetics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Neothetics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of USD 6,637,989 compared to USD 2,484,968 a year ago. Net loss was USD 6,902,380 compared to USD 1,602,238 a year ago. Basic and diluted loss per share was USD 0.50 compared to USD 3.00 a year ago.

Neothetics, Inc. to Report Q1, 2015 Results on May 14, 2015

Neothetics, Inc. announced that they will report Q1, 2015 results at 9:00 AM, Eastern Standard Time on May 14, 2015

Neothetics, Inc., Annual General Meeting, Jun 16, 2015

Neothetics, Inc., Annual General Meeting, Jun 16, 2015., at 09:00 Pacific Standard Time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEOT:US $13.98 USD -0.08

NEOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEOT.
View Industry Companies

Industry Analysis


Industry Average

Valuation NEOT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOTHETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at